The end of the pandemic

Big words — but here is a possible way out, to be walked by each and everyone (as of May 02, 2021: 26 studies, 16 test results, 12 laboratories, (9 in continental europe, 3 in the UK) 37,5% of the results showing cross-immunity)

Three pictures: the vitruvian man, an explosion on Pinterest, and a virus. Sources: Da Vinci would be would turning in his grave…
also see futher below for more information

The pandemic just doesn’t want to go away — despite cross immunity

Corrected Bar chart showing the values ​​of cross-immunity against SARS-CoV-2 from the studies below. Values ​​given as an exact value (blue bar), as a range (blue bar with light gray-blue area) and without a % value (gray). Average value (light blue line): 46%. The sixth of 11 studies was about immunity through antibodies instead of t-cells and therefore has been removed. Below the diagram I show the different thresholds for herd immunity (HIT) that are discussed in science: 20% (some scientists), 42% (Oxford) to 60% (HIT according to the approximation calculation HIT=1–1/Ro), and sometimes up to 90%.

And now?

The first results

80% probability mean 80% probability.
I am not cross-immune or (in the words of the lab:) partially immune against SARS-CoV-2
Three more lab results, where I have the persons consent to publish them anonymously.
Toying with my lab result: extending the spike-C-Term value und changing the SI-value
The values from the two examples above are accordingly to a presentation of the IMD Laboratory: T_cell_response_to_SARS_COV_2_print.pdf
Three more ‘positive’ results, to which I do have the consent to anonymously publish them. By now 37,5% of the results show cross immunity.
Again, no cross immunity. So I did not cross paths with neither HCoV-HKU1, HCoV-OC43, HCoV-NL63, or HCoV-229E, nor with SARS or MERS and also not with SARS-CoV-2.

Where, how, when, how expensive?
The consequences of a phone call, now I have to see a doctor, to get myself punctured …

United Kingdom 🇬🇧














Information about the laboratories — and the fine print